Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 52

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Conjunctivitis allergic+1

Not yet recruiting

Diagnostic Accuracy of Parietaria judaica Pollen Extract (SPT‑RX) in a Skin Prick Test Drug Combination for Adults with Allergic Rhinitis and Controlled Mild Asthma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Betula Pendula Pollen Extract
  • Sponsor:ROXALL Medizin GmbH

Autoimmune haemolytic anaemia+3

Not yet recruiting

Study of cc-97540 CD19‑Targeted NEX‑T CAR T in participants with chronic immune thrombocytopenia and autoimmune hemolytic anemia

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

IgA nephropathy

Not yet recruiting

Study of atrasentan in children aged 2 to <18 years with primary IgA nephropathy to evaluate proteinuria reduction, safety and tolerability

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Atrasentan Hydrochloride
  • Sponsor:Novartis Pharma AG

HIV infection

Not yet recruiting

Study of Emtricitabine, Tenofovir Alafenamide and Bictegravir in Adults with HIV Undergoing Analytical Treatment Interruption

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Emtricitabine
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Type 1 diabetes mellitus

Not yet recruiting

Effect of Verapamil Hydrochloride on Beta Cell Function in Children and Adults Aged 7‑45 with Stage 1 or Stage 2 Type 1 Diabetes (48‑Week Study)

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Verapamil Hydrochloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Hypersensitivity pneumonitis

Not yet recruiting

Efficacy of Prednisolone Metasulfobenzoate Sodium vs Placebo in Adults with Fibrotic Hypersensitivity Pneumonitis: A Randomized Controlled Trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone Metasulfobenzoate Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Neuromyelitis optica spectrum disorder+1

Not yet recruiting

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Cardiac amyloidosis

Not yet recruiting

Serum Transthyretin Levels in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis and Acoramidis: A Within‑Patient Pilot Crossover Study

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Medical University Of Vienna

Rheumatoid arthritis+1

Not yet recruiting

Phase II Study of 99mTc NTP15-5 Imaging to Detect Hand Joint Disease in Patients with Rheumatoid Arthritis and Finger Osteoarthritis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Centre Jean Perrin

VEXAS syndrome

Not yet recruiting

Randomized Study of SIR9900 for Safety and Effectiveness in Patients with VEXAS Syndrome

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Amyloidosis

Not yet recruiting

Evaluation of belantamab mafodotin plus drug combination in adult patients with newly diagnosed light chain amyloidosis

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Glaxosmithkline Research & Development Limited

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.